Literature DB >> 28961801

Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis.

Marco Ripa1,2, Olga Rodríguez-Núñez2, Celia Cardozo2, Antonio Naharro-Abellán3, Manel Almela4, Francesc Marco4, Laura Morata2, Cristina De La Calle2, Ana Del Rio2, Carolina Garcia-Vidal2, María Del Mar Ortega2, María De Los Angeles Guerrero-León2, Csaba Feher2, Berta Torres2, Pedro Puerta-Alcalde2, Josep Mensa2, Alex Soriano2, José Antonio Martínez2.   

Abstract

OBJECTIVES: To evaluate the influence on mortality of empirical double-active combination antimicrobial therapy (DACT) compared with active monotherapy (AM) in septic shock patients.
METHODS: A retrospective study was performed of monomicrobial septic shock patients admitted to a university centre during 2010-15. A propensity score (PS) was calculated using a logistic regression model taking the assigned therapy as the dependent variable, and used as a covariate in multivariate analysis predicting 7, 15 and 30 day mortality and for matching patients who received DACT or AM. Multivariate models comprising the assigned therapy group and the PS were built for specific patient subgroups.
RESULTS: Five-hundred and seventy-six patients with monomicrobial septic shock who received active empirical antimicrobial therapy were included. Of these, 340 received AM and 236 DACT. No difference in 7, 15 and 30 day all-cause mortality was found between groups either in the PS-adjusted multivariate logistic regression analysis or in the PS-matched cohorts. However, in patients with neutropenia, DACT was independently associated with a better outcome at 15 (OR 0.29, 95% CI 0.09-0.92) and 30 (OR 0.25, 95% CI 0.08-0.79) days, while in patients with Pseudomonas aeruginosa infection DACT was associated with lower 7 (OR 0.12, 95% CI 0.02-0.7) and 30 day (OR 0.26, 95% CI 0.08-0.92) mortality.
CONCLUSIONS: All-cause mortality at 7, 15 and 30 days was similar in patients with monomicrobial septic shock receiving empirical double-active combination therapy and active monotherapy. However, a beneficial influence of empirical double-active combination on mortality in patients with neutropenia and those with P. aeruginosa infection is worthy of further study.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28961801     DOI: 10.1093/jac/dkx315

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Rationalizing antimicrobial therapy in the ICU: a narrative review.

Authors:  Jean-François Timsit; Matteo Bassetti; Olaf Cremer; George Daikos; Jan de Waele; Andre Kallil; Eric Kipnis; Marin Kollef; Kevin Laupland; Jose-Artur Paiva; Jesús Rodríguez-Baño; Étienne Ruppé; Jorge Salluh; Fabio Silvio Taccone; Emmanuel Weiss; François Barbier
Journal:  Intensive Care Med       Date:  2019-01-18       Impact factor: 17.440

2.  Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates.

Authors:  Natalija Karabasevic; Jason A Roberts; Luke Stronach; Saiyuri Naicker; Steven C Wallis; Fredrik Sjövall; Fekade Sime
Journal:  Antimicrob Agents Chemother       Date:  2022-04-07       Impact factor: 5.938

Review 3.  Timing of antibiotic therapy in the ICU.

Authors:  Marin H Kollef; Andrew F Shorr; Matteo Bassetti; Jean-Francois Timsit; Scott T Micek; Andrew P Michelson; Jose Garnacho-Montero
Journal:  Crit Care       Date:  2021-10-15       Impact factor: 9.097

4.  Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.

Authors:  Minyon L Avent; Kate L McCarthy; Fekade B Sime; Saiyuri Naicker; Aaron J Heffernan; Steven C Wallis; David L Paterson; Jason A Roberts
Journal:  Microbiol Spectr       Date:  2022-04-20

5.  Bloodstream infections in critically ill patients: an expert statement.

Authors:  Jean-François Timsit; Etienne Ruppé; François Barbier; Alexis Tabah; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2020-02-11       Impact factor: 17.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.